Allogeneic hematopoietic SCT is a curative treatment for a variety of hematological malignancies and genetic diseases. There is a continuous search for novel conditioning regimens that will reduce SCT-related toxicity while retaining maximal antimalignancy effect. Treosulfan (L-threitol-1,4-bis-methanesulfonate; dihydroxybusulfan) was initially used in the treatment of certain solid tumors. Preclinical studies showed that it has a myeloablative effect on committed and non-committed stem cells. It has potent immunosuppressive characteristics, more prominent than its related chemotherapy agent BU, which makes it an attractive candidate for the use in conditioning regimens before allo-SCT. It is also associated with a favorable toxicity profile with little extramedullary toxicity. The combination of fludarabine and treosulfan was explored in several studies in patients not eligible for standard myeloablative conditioning, and data are rapidly emerging. This regimen is associated with consistent engraftment. A limited non-relapse mortality (NRM) rate in the range of 9-28% was observed. This rate is promising considering the patients selected and results from low rates of organ toxicity as well as acute and chronic GVHD. The regimen was also associated with low relapse rates of 5-30% depending on disease status at SCT. Together with low NRM rate, this resulted in favorable survival in the range of 40-80%. Promising results were seen in myelodysplastic syndrome (survival 36-70%) and leukemia in remission (60-70%). Randomized prospective studies will be needed to better define the role of treosulfan-based regimens in SCT.
Introduction
Allogeneic hematopoietic SCT is a potentially curative treatment for a variety of hematological malignancies. The therapeutic effect of SCT is mediated by both the administration of high-dose chemoradiotherapy and the induction of the graft-vs-malignancy effect by immune competent cells in the graft. 1 The conditioning regimen given before SCT has two aims: ablation or reduction of the underlying malignancy and suppression of host immunity to allow donor cell engraftment. Several regimens are used for these goals. Bacigaluopo et al. 2 defined conditioning regimen intensity based on the expected duration and reversibility of cytopenia after SCT. Myeloablative conditioning (MAC) results in irreversible cytopenia in most patients, and stem-cell support after SCT is required. Truly non-myeloablative regimens cause minimal cytopenia and can theoretically be given without stem-cell support. Reduced-intensity conditioning (RIC) regimens cause profound cytopenia and should be given with stem cells, but cytopenia may not be irreversible.
Historically, more emphasis was given to the intensity of the conditioning regimens. Myeloablative regimens were used for maximal reduction of the underlying malignancy. However, despite marked improvement in transplantation outcome in recent years, 3 these regimens are still associated with relatively high treatment-related toxicity and are limited to younger and medically fit patients. Over the last decade, the pendulum turned more toward induction of graft-vs-malignancy as the primary goal of SCT. A plethora of non-myeloablative and RIC regimens have been introduced to achieve this aim. These regimens have been able to reduce transplant-related toxicities and to allow SCT in elderly and medically infirm patients; however, relapse rates after SCT may be higher than after MAC. 1 Outcome after SCT is determined by the balance between the ability to eradicate the malignancy and to survive transplant-related complications, such as organ toxicities, infections and the complications of acute GVHD (aGVHD) and chronic GVHD. An optimal conditioning regimen will allow consistent engraftment, maximal malignancy elimination and minimal toxicity. Reducing toxicity without compromising SCT efficacy could be of significant benefit, and there is still the need to design novel regimens that would achieve this goal.
In this review, we discuss the introduction of treosulfan (L-threitol-1,4-bis-methanesulfonate; dihydroxybusulfan) into pretranspalnt regimens. We report the results of preclinical and clinical studies and the agent properties in determining SCT outcomes.
Treosulfan: clinical pharmacology
Treosulfan (is a precursor of L-diepoxybutane produced in-vivo via the corresponding monoepoxide (Figure 1 ). The conversion is pH-and temperature-dependent intramolecular nucleophilic substitution. 4 It is non-enzymatic and occurs under physiological conditions. 5 Both epoxide species are assumed to be responsible for the DNA alkylation, interstrand cross-linking, chromosomal aberration and induction of apoptosis. 6 This is in contrast to BU, which is a direct alkylating agent. Also in contrast to BU, treosulfan is soluble in water and therefore can be easily applied i.v.
The half-life of treosulfan was determined to be in the range of 1.8-2 h. 4, 7 Clinical and pharmacology studies using HPLC analysis of blood and urine samples showed linear correlation between the area under the curve and maximum plasma concentration (Cmax).
Treosulfan has shown antitumor activity for a variety of solid tumors. [8] [9] [10] [11] It is approved for the treatment of ovarian carcinoma in a number of European countries. 12, 13 Since the early 1980s, clinical studies with the i.v. formulation of treosulfan have been conducted predominantly in patients with ovarian cancer as a single drug or in combination with other cytotoxic drugs, such as cisplatin or gemcitabin. 12, 13 The conventional tolerated doses were 5-8 g/m 2 i.v. The most common toxicity is hematological, which limits the maximal tolerated dose to 10 g/m 2 every 4 weeks. 14 Other mild toxicities in the setting of treatment of solid tumors were gastrointestinal (mucositis/stomatitis and diarrhea) or cutaneous side effects. 7, 14 Phase-I studies have shown that when administered with autologous stem-cell support, the treosulfan dose can be escalated to 47 g/m 2 . 7 Treosulfan was tested in autologous transplants in patients with lymphoma and myeloma. 7, 15, 16 Preclinical studies
In vitro studies Treosulfan was studied in various hematological malignancies. It was found to have therapeutic effects in various in vitro and in vivo models of AML, ALL and multiple myeloma (MM). [17] [18] [19] [20] [21] It reduced the viability of human myeloid leukemia cells, even at low concentrations of 10 and 30 mm, by more than 70 and 90%, respectively. 22 Although it is inadequate to correlate in vitro data with plasma levels and response rates in vivo, it is notable that in the in vitro experiments, the concentrations needed to eliminate more than 90% of the leukemia cells were in the range of 100 mM; concentrations that are 10-fold lower than the plasma levels achievable in patients given conventional doses (1 mmol/L). 4, 7 Treosulfan was more active than BU against leukemic cells of children. 17 In 23 childhood ALL and AML samples, IC50 values were four times lower than in the primary leukemic cells than for BU (median IC50: 31 and 126 mmol/L, respectively). Similarly, the concentrations shown to be effective in these experiments were 10-fold lower than those that can be achieved in the blood of patients. 4, 23 Similar results were shown for acute and chronic myelogenous leukemia, where treosulfan is a potent inducer of cell death, equal or superior to BU. 20, 24 Treosulfan has a broad anti-stem-cell effect against both primitive and committed stem cells. 25, 26 In contrast to BU, which preferentially depletes primitive stem cells, treosulfan was found to deplete committed progenitors as well as primitive stem cells in vitro. 26 In addition, agar colony assays demonstrated that the stem cell toxicity of treosulfan is superior to that achieved by BU or CY. 27 The treatment of myeloma cell lines with treosulfan led to apoptosis in cell lines in a dose-and time-dependent manner. Furthermore, in MM cell lines, the cytotoxicity of treosulfan was equal or superior to that of melphalan. Treosulfan was capable of inducing cell death in 63.6± 23.9% of primary myeloma cells, whereas treatment with the same concentration of melphalan showed 59.7 ± 26% cell death.
Treosulfan was shown by Schmidmaier et al. 28 to induce considerable damage to a BM stromal cell line and death of primary BM stromal cells. Impaired stromal cell viability could reduce the integrin binding of malignant and stromal cells, and diminish cell-adhesion-mediated drug resistance so that enhanced tumor cell apoptosis can be expected after HSCT. 28 In vivo models Following the findings of in vitro activity, Borgmann et al. 29 investigated in vivo animal models of treosulfan. They examined three human ALL cell lines xenotransplanted 30 studied the myeloablative properties of treosulfan in mice and compared them to those of CY and BU using a clonogenic assay. Treosulfan induced an immediate, strong and persisting myeloablative effect, comparable to that of BU. Moreover, when administered in combination with T-cell-depleted donor BM cells, 31, 32 it provided permanent donor-specific tolerance and stable mixed multilineage chimerism across fully disparate and haploidentical MHC barriers.
The ability of treosulfan to induce lymphocyte depletion was investigated in animal models. It was observed that administration of treosulfan caused splenic B-and T-cell depletion, which was much stronger and more durable than that caused by CY or BU. Moreover, it was shown that both the CD4 and CD8 T-cell subsets are equally depleted by treosulfan treatment. 30 Sjoo et al. 30 observed that treatments with treosulfan and CY resulted in induction of different patterns of inflammatory cytokine production. Proinflammatory cytokines including TNF-a, IFN-g and IL-2 are considered a part of the cytokine storm and have an important role in the pathogenesis of GVHD causing injury to the salivary glands tissue 33 and veno-occlusive disease (VOD).
34-37
Administration of either treosulfan or CY may lead to cytokine release, which may activate GVHD and/or VOD after BMT. However, the amount of IL-2 generated in treosulfan-treated mice was very low decreasing the probability of these complications after transplantation. In summary of these preclinical studies, treosulfan treatment results in rapid, profound and stable myelosuppression due to its dual effect on committed and noncommitted stem cells. It exhibits immunosuppressive characteristics that are superior to those of CY and BU, which may facilitate stem cell engraftment. It may also result in a lower risk of GVHD because of more favorable cytokine release pattern. These properties make treosulfan an attractive candidate for the use in conditioning regimens before allogeneic HSCT (Table 1) .
Clinical results in allo-SCT

Regimens
The biological properties of treosulfan, including its effective antileukemic potential, the immunosuppressive effects and the low extramedullary toxicity, led to design of treosulfan-based regimens for allo-SCT, which included escalated doses of treosulfan. The rationale was to improve myeloablation and disease eradication while maintaining reduced toxicity after allogeneic transplantation. In the majority of studies, treosulfan was combined with fludarabine. Fludarabine adds to the immune suppression potential of the regimen. It has low extramedullary toxicity and although it is not a direct antileukemic agent, it may synergize with the antileukemic effect of alkylating agents by inhibition of repair of DNA damage induced by these agents. 38 The common regimen consists of treosulfan (10-14 g/m 2 i.v. over 2 h daily from days À6 to À4) and fludarabine (30 mg/m 2 i.v. daily over 30 min from days À6 to À2). [39] [40] [41] [42] [43] [44] [45] [46] For patients with unrelated donors, antithymocyte globulin (for example, ATG Fresenius, Fresenius Biotech, Munich, Germany (5-10 mg/kg)) was given i.v. daily from days À3 to À1. One series combined treosulfan with high-dose CY, similar to the BUCy regimen. 23 Clinical data of treosulfan use are rapidly emerging. The main indication for SCT was AML and myelodysplastic syndrome (MDS); however, several studies also included patients with ALL, lymphoma and myeloma. Most series with treosulfan-based protocols are still of small numbers of patients, heterogeneous patient characteristics, large variety of underlying diseases and short follow-up times. 23, 40, 43, 44, 46 Several studies included more homogeneous diseases, but were still based on small number of patients. 41, 42, 45, 47 The main findings of currently available studies are summarized in Table 2 .
Engraftment and chimerism
In most studies using treosulfan for conditioning, engraftment was rapid, regular and sustained. The median time to engraftment ranged from 14 to 16 days. Secondary failure of engraftment was only rarely documented. 43 In our study that included patients with AML and Treosulfan-based conditioning I Danylesko et al MDS, 41 the neutropenia started earlier than seen in RIC studies. Neutropenia was first detected on median day 0, compared with median day þ 6 after RIC consisting of fludarabine and BU, and more similar to the kinetics of MAC. 48 We assumed that the reason for earlier and therefore more prolonged neutropenia compared with BU was the preferential depletion of primitive stem cells by BU, whereas treosulfan was found to deplete committed progenitors as well as primitive stem cells in vitro. 25, 26 In their earlier report, Casper et al. 40 showed that complete donor chimerism, defined as more than 95% donor cells in the BM, was reached on day 14 by 70% of the patients and on day 28 by 81%; 2 patients had complete donor chimerism when first tested on day 56 and 1 patient had reached complete chimerism by day 56. Other studies showed similar or better results. In the more homogeneous patient group with only AML and MDS, we showed that 19 of the 21 patients with initial engraftment had complete donor chimerism (X99% donor) at 1 month after SCT. 41 This supports the notion that fludarabine/treosulfan combination can be considered a fully intensive regimen rather than a non-myeloablative regimen, which is often associated with initial mixed chimerism. 49 Early achievement of complete chimerism may be important for rapid induction of graft-vs-malignancy effect and limiting of early relapse. 50 Toxicity and GVHD Table 1 outlines the major toxicities of treosulfan compared with BU. BU concentrates in the liver, lung, brain and kidneys 23 and complications include VOD, 23 interstitial pneumonia, hemorrhagic cystitis, permanent alopecia, convulsions and mucositis. 23 Treosulfan-containing regimens are associated with relatively limited extramedullary toxicity. Treosulfan-based conditioning is relatively well tolerated, 40, 43, 45, 46 with a dose that can be escalated up to 3 Â 14 g/m 2 , with no change in the favorable toxicity profile. The main toxicity is grade IV hematotoxicity, which was observed in most of the patients. Patients required multiple packed cells and platelet transfusions (7.3 ± 5.5 and 6.7 ± 6.1, respectively). The number of transfused concentrates was not dependant on treosulfan dose. 43 Severe gastrointestinal toxicity is limited. Casper et al. 43 reported an incidence of grade III and IV mucositis/ stomatitis of 6% and diarrhea of 5%. Other studies reported that mucositis did not exceed grade II 40 or III, 45 and one-third of the patients remained free of any signs of mucositis. 40 Grade III mucositis requiring i.v. narcotics occurred in six patients (25%) in our study. 41 Hilgendorf et al. 45 reported, when comparing treosulfan and TBIbased MAC, that the frequency of grade I/II mucositis was comparable, 57.9 vs 51.7%, respectively. Grade III/IV mucositis occurred in 10.5 vs 20.7% of patients, respectively. Of note, no grade IV mucositis was observed in treosulfan-treated patients. However, the difference was not statistically significant (P ¼ 0.292). 45 Certain toxic side effects reported after RIC were less prevalent in treosulfan-based transplants or did not occur in these patients. Although reduced-dose combinations with BU may still lead to severe hepatic toxicity 51 or to VOD, 39,52 the liver toxicity (alanine transaminase/aspartate aminotransferase elevation) seen with treosulfan was transient and did not exceed grade III. 40 No VOD occurred in the patients treated with treosulfan. 40, 43, 45, 46, 53, 54 Our study was somewhat different. 41 National Cancer Institute (NCI) grade III and IV elevation occurring in nine and two patients, respectively (total 46%). Two patients in our cohort died of multiorgan failure associated with VOD. 41 These two patients were heavily transfused patients with MDS, which may have predisposed them to organ toxicity. In a multicenter prospective phase-II German study in patients with ALL using treosulfan, etoposide and CY, the toxicity was moderate including VOD (6%) and liver toxicity grades III (8%) and IV (3%). 55 Two cases of severe seizures (onset on days 6 and 22 after transplantation) were observed in the dose group of 3 Â 14 g/m 2 treosulfan. These occurred in the context of a severe intracerebral hemorrhage in one patient and a lifethreatening cerebral infection in the other. None of the NCI Common Terminology Corterea for Adverse Events (CTCAE) grade III and IV seizures were considered drug related. 43 Unlike BU, there is no need for prophylactic anticonvulsant treatment.
Pneumonitis and pulmonary toxicity, 51, [56] [57] [58] or severe left ventricular failure/cardiac toxicity, 56, 59 that was previously reported with fludarabine and reduced-dose BU or melphalan combinations were not observed with Treosulfan.
GVHD rates reported by several studies were also limited. In our study, 41 the rate of aGVHD was low reaching only 15%, despite the high proportion of patients having unrelated donors. Casper et al., 53 applying treosulfan 3 Â 14 g/m 2 for AML patients reported that the incidence of grade III and IV aGVHD was 21% and extensive chronic GVHD was only 16%, whereas Hilgendorf et al. 45 reported that the rates of aGVHD were 72.4% (I and II 58.6% and III and IV 13.8%) in the TBI group and 58% (I and II 36.9% and III and IV 21.1%) in the treosulfan group (P ¼ 0.001). Lower incidence of aGVHD was reported by Kroger et al. 55 in patients with ALL. aGVHD grade II-IV and grade III/IV was noted in 22 and 11%, respectively.
Chronic GVHD occurred in 56% of patients after conditioning with TBI and in 72% of patients after treosulfanbased conditioning in Hilgendorf study (P ¼ 0.348). The proportion of extensive GVHD was 28 vs 50%, respectively (P ¼ 0.204). 45 Kroger et al. 55 also showed lower incidence of chronic GVHD; 27% by 1 year, which was extensive in 7% of the patients.
These toxicities resulted in non-relapse mortality (NRM) in the range of 9-28%. 23, [40] [41] [42] [43] 46, 47, 54, 60 This range is comparable with non-MAC. 61, 62 The lowest NRM rate has been shown in the multicenter German study in patients with ALL. After a median follow-up of 12 months, the cumulative incidence of NRM at 1 year was only 9%. 55 Considering the selection of poor-risk patients for these studies, this treatment-related mortality rate compares favorably with that of other reduced-intensity approaches. 56, 57, [63] [64] [65] In general, NRM was mostly related to infections and GVHD, and not to direct organ toxicity related to the conditioning regimen. 40 Larger doses of treosulfan were not associated with a higher NRM rate. Similar and even better results for NRM were shown when treosulfan doses were escalated up to 3 Â 14 g/m 2 , 53, 54 In the study of Casper et al., 53 the regimen was associated with a low incidence of grade III/IV non-hematological toxicities, which is also reflected in the very low NRM (3% at day þ 100, 9% at 1 year and 11% at 2 years).
A favorable 100-day treatment-related mortality of 10% was also found in MM patients. 47 These patients are often susceptible to high rates of NRM. This rate is comparable to that observed using RIC protocols, 66, 67 and was significantly lower than the NRM of up to 45% observed after conventional conditioning in MM patients. 68 A relatively low NRM was seen in our group of patients with second transplants. 69 Although the majority of patients were heavily pretreated, many with active and refractory leukemia, the cumulative incidence of NRM was 30%.
Relapse and survival Survival after SCT is dependent on the relative incidence of relapse and NRM. As discussed NRM associated with treosulfan-based conditioning may be relatively low. Similarly, relapse rate in most studies was also favorable, leading to improved overall outcome. Reported relapse rates of 5-37%, may indicate potent antitumoral effect of treosulfan. 40 These relapse rates are similar to those associated with myeloablative regimens in eligible patients. 48 The efficacy of this regimen was tested in several diseases and settings. Treosulfan-based conditioning has been relatively successful in patients with MDS. A comparative study of MDS patients showed that patients with comorbidities, who were given treosulfan-based conditioning, had significantly lower relapse rates compared with the standard high-dose TBI-based approach (5% at 3 years vs 34%, P ¼ 0.019). 45 Combined with the low NRM, this translated to a significantly better 3-year relapse-free survival (54% vs 11%; P ¼ 0.0455) and a trend to a better 3-year OS (54 vs 22%; P ¼ 0.1514) compared with TBIbased conditioning. 45 Ruutu et al. 54 showed favorable results in patients with MDS. The relapse/progression disease found in this study was only 16% at 2 years, and the estimated 2-year OS and disease-free survival were 71 and 67%, respectively. 54 In our study, we observed promising results in previously untreated MDS, mostly patients with excess of blasts. OS after upfront SCT was 61%. 60 These results compare favorably with other RIC studies in MDS showing 3-year OS that ranges from 20 to 48%, relapse-free survival between 22 and 40%, and a 3-year NRM ranging from 22 to 37%. [70] [71] [72] [73] Treosulfan was also studied extensively in patients with AML. Outcome in AML patients is strongly correlated with disease status at SCT. A prospective phase-II study in 75 AML patients was conducted by Casper et al. 53 All patients were in CR at entry into the study (80% CR1, 17% CR2 and 3% CR3). Treosulfan was administered in a relatively high dose (14 g/m 2 on days À6 to À4). The 2-year relapse rate, 1 and 2 years after transplantation was 30 and 34%, respectively. 53 OS and disease-free survival at 2 years reached 61 and 55%, respectively. 53 Nemecek et al.
44
reported 2-year cumulative incidence of relapse of 33% (34% for AML in first remission, 50% for AML or ALL beyond first remission and 63% for AML in refractory relapse). With a median follow-up of 22 months, the 2-year relapse-free survival for all patients was 58 and 88% for patients without high-risk cytogenetics. 44 In our cohort of patients with poor prognostic factors due to comorbidities, age, extensive previous therapy, advanced disease and low Karnofsky score, 60 the cumulative incidence of relapse was 35% at 3 years. Considering that only 26% of patients were in any CR at the time of SCT, this rate seems promising. With a median follow-up 16 months, AML patients in CR1 had OS of 68%. The efficacy of the regimen in controlling advanced leukemia was much more limited with an OS of 26%.
Baronciani reported a less favorable outcome compared with data reported by Shimoni et al. 23, 41 In this series of patients, 74 most failures were due to the recurrence or progression of the underlying malignancy. The observed high relapse rate was because of the fact that this study included patients with more advanced disease. Only 7 out of 46 patients (15%) were in first CR and patients with non-myeloid leukemia were included. When the authors separately analyzed PFS in patients transplanted in remission and particularly in patients with AML in remission, the results were comparable to those reported by other authors.
Less data are available for ALL and MM. Kroger et al.
55
showed 37% one-year relapse rate in patients with ALL. The estimated 1-year disease-free survival was 56% and significantly better for patients transplanted in CR 1 vs second or higher CR (68 vs 15%, P ¼ 0.05). 55 The estimated 1-year OS was 81%.
Schmidt-Hieber et al. 47 investigated the conditioning regimen with treosulfan and fludarabine before allo-SCT in MM patients. These patients were heavily pretreated and a majority showed disease progression before allo-SCT.
Although NRM was limited, the majority of these patients relapsed in a median PFS of 180 days. 47 Estimated OS at 2 years was 58%.
Treosulfan-containing regimens in unique settings
Non-malignant diseases Allogeneic HSCT still remains the only curative treatment for patients with some inherited diseases. GVL is not important in this setting and a regimen with reduced toxicity and a low rate of GVHD is of particular value.
Greystoke et al. 75 studied 32 children with non-malignant diseases, including primary immunodeficiency, metabolic disorders and malignant infantile osteopetrosis, following SCT with treosulfan-based conditioning. Toxicity included only mild mucositis and dermatologic toxicity, and no VOD. In all, 28 patients (87.5%) achieved donor cell engraftment. A total of 27 patients (84%) survived with a median follow-up of 417 days. There were four late deaths due to progression of the underlying disease, GVHD or infections. 75 Although some reports have documented the feasibility of using reduced-intensity preparative regimens for successfully treating patients with thalassemia major, a high incidence of graft failure has been frequently reported. 76 Recently, a treosulfan-based myeloablative regimen was shown to improve the outcome of thalassemia major patients treated with an allograft. 77, 78 In a phase I-II, non-randomized, clinical trial, 20 young patients (median age 13 years) with thalassemia major underwent transplantation. 78 The majority of patients benefited from sustained donor engraftment with mild extramedullary toxicity and a low incidence of aGVHD and chronic GVHD (grade II-IV aGVHD 15% and chronic GVHD 7%). Only two patients (10%) developed grade I and II liver toxicity (that is, transient elevation of liver enzymes), respectively, and no case of VOD was diagnosed. No lung, heart and central nervous system toxicity was recorded. The only toxic effect was mucositis (30%). The cumulative incidence of TRM was 5%, with only one patient dying of aGVHD. A total of 19 patients were alive at a median follow-up of 20 months (range 8-28).
Haploidentical SCT
The immunosuppressive properties of treosulfan combined with its non-toxic myeloablative characteristics led to the inclusion of treosulfan in conditioning regimens for haploidentical transplants. Beier et al. 79 reported multicenter retrospective analysis of 92 children with malignant and non-malignant diseases following SCT with treosulfanbased conditioning. Twelve from them received a haploidentical graft from family donors, and two a combination of a cord and haploidentical graft. Only one engraftment failure in patient with thalassemia was reported. All other patients engrafted rapidly. Toxicity and GVHD grades were mostly I and II. 79 Peccatori et al. 80 investigated the safety of infusion of T-cell repleted PBSC from haploidentical donor with a combination of rapamycin, mycophenolate and antithymocyte globulin after treosulfan-based conditioning. Inspite of advanced age and phase of disease, cumulative incidence of TRM and relapse incidence were 25% and 44%, respectively. 80 
Second transplants
The low toxicity of treosulfan-based conditioning led to exploring this regimen for second transplants, as this setting is often associated with prohibitive toxicity when standard MAC is attempted. Shimoni et al. 69 studied the combination of fludarabine and treosulfan as a conditioning regimen for second SCT subsequent to a previous autoor allo-SCT. The study included 17 patients, median age of 58 years. The second allo-SCT was given for relapse after a prior SCT or for a secondary AML/MDS in the three patients having autologous SCT for lymphoma and myeloma (Table 2) . Only 4 patients out of 17 were in remission at the time of second SCT. Six patients were chemorefractory and seven patients were transplanted in untreated malignancy. In all, 12 patients engrafted after second SCT, recurrence rate was relatively low, cumulative incidence of 25% 69 and the estimated 2-year OS and disease-free survival were both 45%, 60, 69 Best results were achieved in the group having a second SCT from a second allogeneic donor.
Conclusions
Historically, patients with hematological malignancies could only be given standard MAC regimens and would have been denied SCT if not strictly fit. Improved understanding of transplantation biology in recent years has led to the development of dose-reduced conditioning regimens. These reduced-intensity conditioning regimens allow transplantation in older patients and patients with comorbidities, however, the risk of relapse after SCT may be increased. Several studies have shown that in patients with AML and MDS, outcome after SCT is probably similar after myeloablative and RIC. However, outcome following RIC may be inferior in patients with active disease. 48 Treosulfan is a good candidate to be included in conditioning regimens. It is effective against different types of malignant cells and it is cytotoxic to committed and more immature hematopoietic progenitors. 25 It is easily administered and converted to the active form by nonenzymatic activation. 5 It has myeloablative and immunosuppressive characteristics, but is associated with limited non-hematological toxicity. The combination of fludarabine and treosulfan shares properties of both RIC and myeloablative regimens. It is associated with prompt engraftment and complete donor chimerism similar to MAC. It has effective antileukemia properties, and posttransplant relapse rates are relatively low, similar to the myeloablative counterparts. On the other hand, the regimen has limited toxicity, relatively low rates of aGVHD and NRM similar to those seen in RIC. The regimen can therefore be considered a fully intensive regimen but with reduced toxicity or what is now defined as a reduced toxicity myeloablative regimen. The net effect is a possible improved outcome, especially in patients with acute leukemia in remission and MDS. Patients with advanced disease are probably better rescued with standard MAC.
Conditioning with a treosulfan-based regimen offers a promising alternative to RIC in patients not eligible for MAC. It may also turn out to be an alternative to MAC in eligible patients; however, there are no available comparative studies in these patients. Further studies with more accurately defined groups of patients are needed to compare treosulfan/fludarabine with other widely used regimens. A comprehensive prospective randomized study in AML, ALL and MDS patients, which is currently under way in several European countries, may help to clarify the role of treosulfan in allo-SCT.
Conflict of interest
The authors declare no conflict of interest.
